Analysts See $1.21 EPS for Valeant Pharmaceuticals Intl (VRX); Veracyte (VCYT) Had 5 Bulls

October 17, 2017 - By Henry Gaston

Analysts expect Valeant Pharmaceuticals Intl Inc (TSE:VRX) to report $1.21 EPS on November, 14.They anticipate $0.81 EPS change or 40.10% from last quarter’s $2.02 EPS. T_VRX’s profit would be $420.15 million giving it 3.32 P/E if the $1.21 EPS is correct. After having $1.41 EPS previously, Valeant Pharmaceuticals Intl Inc’s analysts see -14.18% EPS growth. About 650,010 shares traded. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has 0.00% since October 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering Veracyte (NASDAQ:VCYT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Veracyte had 8 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 14 by BTIG Research. The firm has “Buy” rating by Janney Capital given on Tuesday, November 29. Cantor Fitzgerald initiated Veracyte Inc (NASDAQ:VCYT) on Friday, December 18 with “Buy” rating. The firm earned “Overweight” rating on Friday, August 14 by Piper Jaffray. See Veracyte Inc (NASDAQ:VCYT) latest ratings:

26/09/2017 Broker: Janney Capital Rating: Buy
31/08/2017 Broker: BTIG Research Rating: Buy New Target: $13.0

Veracyte, Inc. is a genomic diagnostics company. The company has market cap of $303.35 million. The Firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It targets diseases in which patients undergo invasive diagnostic procedures.

About 30,766 shares traded. Veracyte Inc (NASDAQ:VCYT) has risen 56.46% since October 17, 2016 and is uptrending. It has outperformed by 39.76% the S&P500.

Since May 16, 2017, it had 0 buys, and 1 sale for $17,986 activity. $17,986 worth of stock was sold by TREU JESSE I on Tuesday, May 16.

Investors sentiment decreased to 1.88 in Q2 2017. Its down 0.45, from 2.33 in 2017Q1. It is negative, as 7 investors sold Veracyte Inc shares while 19 reduced holdings. 15 funds opened positions while 34 raised stakes. 21.14 million shares or 2.38% more from 20.65 million shares in 2017Q1 were reported. Federated Investors Pa reported 0.01% of its portfolio in Veracyte Inc (NASDAQ:VCYT). Blackrock has 0% invested in Veracyte Inc (NASDAQ:VCYT). Manufacturers Life Ins The, a Ontario – Canada-based fund reported 22,961 shares. Texas-based Bridgeway Mngmt has invested 0.04% in Veracyte Inc (NASDAQ:VCYT). Gsa Capital Partners Ltd Liability Partnership reported 0.02% in Veracyte Inc (NASDAQ:VCYT). Eventide Asset Management Limited Liability Corporation stated it has 2.13M shares or 1.11% of all its holdings. Deutsche Comml Bank Ag accumulated 28,332 shares. Sg Americas Securities Limited Liability invested in 12,404 shares or 0% of the stock. Meeder Asset reported 803 shares or 0% of all its holdings. Da Davidson invested 0% in Veracyte Inc (NASDAQ:VCYT). Royal National Bank & Trust Of Canada reported 0% in Veracyte Inc (NASDAQ:VCYT). Sei invested in 3,568 shares or 0% of the stock. Strs Ohio holds 0% in Veracyte Inc (NASDAQ:VCYT) or 37,200 shares. Legal And General Group Inc Pcl accumulated 3,460 shares. Nationwide Fund Advsrs invested in 0% or 13,235 shares.

Among 4 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Valeant Pharmaceuticals International had 35 analyst reports since October 20, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, January 26 by RBC Capital Markets. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Monday, November 28. On Monday, January 23 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. Scotia Capital maintained Valeant Pharmaceuticals Intl Inc (TSE:VRX) rating on Wednesday, January 11. Scotia Capital has “Sector Perform” rating and $17 target. RBC Capital Markets maintained the stock with “Sector Perform” rating in Monday, June 27 report. The stock has “Sector Perform” rating by RBC Capital Markets on Friday, June 9. The firm has “Sector Perform” rating given on Wednesday, September 7 by RBC Capital Markets. On Monday, June 20 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Equal Weight” rating by Morgan Stanley on Thursday, December 15. On Friday, November 18 the stock rating was maintained by RBC Capital Markets with “Sector Perform”.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has market cap of $5.58 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.